China Oncology Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis
Description
China Oncology Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis
China Oncology Drugs Market is anticipated to reach US$ 35.24 Billion by 2027. Cancer is among China’s high-priority disease areas, with patients experiencing a significant health burden. Hence, the cancer drugs industry is the fastest-growing central therapeutic area in China’s pharmaceutical market. In particular, the increasingly challenging treatment of complex, severe cancerous diseases through drugs has generated unmet medical needs, leading to the promising market potential of the China Cancer Drugs Market.
Further, the acceleration of innovation within the oncology drugs industry in China is critical to progress in managing China’s oncology burden. Exceptionally outpacing the growth rate of new cancer cases in China, the oncology drug market in China demonstrates robust growth.
China Oncology Drugs Market Size was US$ 23.70 Billion in 2021
Chinese Drugs Industry has been shaping initiatives grounded in the local environment, assuring that patients receive enhanced treatment options that are accessible and equitable to all. Moreover, recent trends fuelling China’s progress in cancer drugs are innovation. A wave of new biotech’s focused on oncology and improved quality in oncology research is boosting China’s Cancer Drugs Market.
In addition, other key growth drivers for the industry in China include the aging trend of the Chinese population, rising healthcare expenditure, and improving the public medical insurance system. Therefore, driven by multiple factors, the number of new cases of cancer in China treated by drugs has constantly been increasing. According to Renub Research report, China Cancer Drug Industry is expanding at a CAGR of 6.8% during 2021-2027.
Targeted Therapy Is the Most Dominating Segment in China Oncology Drugs Market:
In our report, China Cancer Drug Market covers the cancer therapy market and the cancer drugs market. In terms of therapy, cancer treatment has gone through a long development process in history. Effective therapies include chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy.
In addition, cancer supportive care, which refers to the medical care that focuses on relieving the symptoms caused by cancer treatments to improve the quality of life, has also evolved with the development of various cancer treatment therapies. As per our analysis, By Therapy, Targeted Therapy is the most dominating segment in China Oncology Drug Market.
Lung Cancer Segment Occupies the Largest Oncology Drugs Market Share:
By Indication, our report covers Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, and Kidney Cancer existing in the market. In addition, China looks set to become a primary developer of cancer drugs for the diverse indications infusing regulatory changes to simplify and encourage drug development, which also opens the door for more significant investment by international pharmaceutical brands.
According to Indication, the lung oncology segment occupies the largest oncology drugs market share due to the vast geriatric population in China. Besides, the breast cancer segment is expected to experience the fastest growth due to technological developments in cancer diagnostics and a rise in awareness related to the early diagnosis of cancer.
Key Players:
The major players operating in the China Oncology Drugs Market include Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc. Companies have explored different development pathways to accelerate regulatory approval for faster patient access. Additionally, key players are increasingly entering into R&D partnerships with local Chinese companies to accelerate approval and bring treatment to patients. In addition, companies are also offering schemes to improve affordability to help patients get appropriate treatment.
The COVID-19 Pandemic Disrupted the China Oncology Drugs Market:
The COVID-19 pandemic has had widespread adverse collateral effects on China Cancer Drugs Market. Remarkably, China’s Oncology Drugs Industry was reliant on rapid testing and diagnosis and on timely and coordinated multimodal treatment, all of which had been impacted by the pandemic adversely. However, over time, the initial and enduring effects of the COVID-19 pandemic on the utilization of cancer drugs deteriorated.
Renub Research report titled “China Oncology Drugs Market, by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy) and Hormonal Therapy), Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, Other Cancers), Drugs ( ESAs (Erythropoiesis Stimulating Agents), G-CSFs (Granulocyte-colony Stimulating Factors), Anti-emetics, Bisphosphonates, Opioids, NSAIDs & Others), Companies (Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc)” provides a complete analysis of China Oncology Drugs Market.
Therapy – Market have been covered from 4 viewpoints:
1. Chemotherapy
2. Targeted Therapy
3. Immunotherapy (Biologic Therapy)
4. Hormonal Therapy
Indication – Market have been covered from 10 viewpoints:
1. Blood Cancer
2. Breast Cancer
3. Gastrointestinal Cancer
4. Prostate Cancer
5. Lung Cancer
6. Skin Cancer
7. Ovarian Cancer
8. Cervical Cancer
9. Kidney Cancer
10. Other Cancers
Drugs – Market have been covered from 6 viewpoints:
1. ESAs (Erythropoiesis Stimulating Agents)
2. G-CSFs (Granulocyte-colony Stimulating Factors)
3. Anti-emetics
4. Bisphosphonates
5. Opioids
6. NSAIDs & Others
Company Insights:
• Overview
• Recent Development & Strategies
• Revenue Analysis
Company Analysis:
1. Bristol Myers Squibb
2. Merck
3. Eli Lilly
4. Sino BioPharma
5. F Hoffmann-La Roche AG
6. Johnson & Johnson
7. AbbVie Inc.
8. AstraZeneca plc
China Oncology Drugs Market is anticipated to reach US$ 35.24 Billion by 2027. Cancer is among China’s high-priority disease areas, with patients experiencing a significant health burden. Hence, the cancer drugs industry is the fastest-growing central therapeutic area in China’s pharmaceutical market. In particular, the increasingly challenging treatment of complex, severe cancerous diseases through drugs has generated unmet medical needs, leading to the promising market potential of the China Cancer Drugs Market.
Further, the acceleration of innovation within the oncology drugs industry in China is critical to progress in managing China’s oncology burden. Exceptionally outpacing the growth rate of new cancer cases in China, the oncology drug market in China demonstrates robust growth.
China Oncology Drugs Market Size was US$ 23.70 Billion in 2021
Chinese Drugs Industry has been shaping initiatives grounded in the local environment, assuring that patients receive enhanced treatment options that are accessible and equitable to all. Moreover, recent trends fuelling China’s progress in cancer drugs are innovation. A wave of new biotech’s focused on oncology and improved quality in oncology research is boosting China’s Cancer Drugs Market.
In addition, other key growth drivers for the industry in China include the aging trend of the Chinese population, rising healthcare expenditure, and improving the public medical insurance system. Therefore, driven by multiple factors, the number of new cases of cancer in China treated by drugs has constantly been increasing. According to Renub Research report, China Cancer Drug Industry is expanding at a CAGR of 6.8% during 2021-2027.
Targeted Therapy Is the Most Dominating Segment in China Oncology Drugs Market:
In our report, China Cancer Drug Market covers the cancer therapy market and the cancer drugs market. In terms of therapy, cancer treatment has gone through a long development process in history. Effective therapies include chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy.
In addition, cancer supportive care, which refers to the medical care that focuses on relieving the symptoms caused by cancer treatments to improve the quality of life, has also evolved with the development of various cancer treatment therapies. As per our analysis, By Therapy, Targeted Therapy is the most dominating segment in China Oncology Drug Market.
Lung Cancer Segment Occupies the Largest Oncology Drugs Market Share:
By Indication, our report covers Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, and Kidney Cancer existing in the market. In addition, China looks set to become a primary developer of cancer drugs for the diverse indications infusing regulatory changes to simplify and encourage drug development, which also opens the door for more significant investment by international pharmaceutical brands.
According to Indication, the lung oncology segment occupies the largest oncology drugs market share due to the vast geriatric population in China. Besides, the breast cancer segment is expected to experience the fastest growth due to technological developments in cancer diagnostics and a rise in awareness related to the early diagnosis of cancer.
Key Players:
The major players operating in the China Oncology Drugs Market include Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc. Companies have explored different development pathways to accelerate regulatory approval for faster patient access. Additionally, key players are increasingly entering into R&D partnerships with local Chinese companies to accelerate approval and bring treatment to patients. In addition, companies are also offering schemes to improve affordability to help patients get appropriate treatment.
The COVID-19 Pandemic Disrupted the China Oncology Drugs Market:
The COVID-19 pandemic has had widespread adverse collateral effects on China Cancer Drugs Market. Remarkably, China’s Oncology Drugs Industry was reliant on rapid testing and diagnosis and on timely and coordinated multimodal treatment, all of which had been impacted by the pandemic adversely. However, over time, the initial and enduring effects of the COVID-19 pandemic on the utilization of cancer drugs deteriorated.
Renub Research report titled “China Oncology Drugs Market, by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy) and Hormonal Therapy), Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, Other Cancers), Drugs ( ESAs (Erythropoiesis Stimulating Agents), G-CSFs (Granulocyte-colony Stimulating Factors), Anti-emetics, Bisphosphonates, Opioids, NSAIDs & Others), Companies (Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc)” provides a complete analysis of China Oncology Drugs Market.
Therapy – Market have been covered from 4 viewpoints:
1. Chemotherapy
2. Targeted Therapy
3. Immunotherapy (Biologic Therapy)
4. Hormonal Therapy
Indication – Market have been covered from 10 viewpoints:
1. Blood Cancer
2. Breast Cancer
3. Gastrointestinal Cancer
4. Prostate Cancer
5. Lung Cancer
6. Skin Cancer
7. Ovarian Cancer
8. Cervical Cancer
9. Kidney Cancer
10. Other Cancers
Drugs – Market have been covered from 6 viewpoints:
1. ESAs (Erythropoiesis Stimulating Agents)
2. G-CSFs (Granulocyte-colony Stimulating Factors)
3. Anti-emetics
4. Bisphosphonates
5. Opioids
6. NSAIDs & Others
Company Insights:
• Overview
• Recent Development & Strategies
• Revenue Analysis
Company Analysis:
1. Bristol Myers Squibb
2. Merck
3. Eli Lilly
4. Sino BioPharma
5. F Hoffmann-La Roche AG
6. Johnson & Johnson
7. AbbVie Inc.
8. AstraZeneca plc
Table of Contents
145 Pages
- 1. Introduction
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. China Cancer Drugs Market
- 6. Market Share – China Oncology Drugs Market
- 6.1 By Therapy
- 6.2 By Indication
- 6.3 By Drugs
- 7. Therapy– China Oncology Drugs Market
- 7.1 Chemotherapy
- 7.2 Targeted Therapy
- 7.3 Immunotherapy (Biologic Therapy)
- 7.4 Hormonal Therapy
- 8. Indication– China Oncology Drugs Market
- 8.1 Blood Cancer
- 8.2 Breast Cancer
- 8.3 Gastrointestinal Cancer
- 8.4 Prostate Cancer
- 8.5 Lung Cancer
- 8.6 Skin Cancer
- 8.7 Ovarian Cancer
- 8.8 Cervical Cancer
- 8.9 Kidney Cancer
- 8.11 Other Cancers
- 9. Drugs– China Oncology Drugs Market
- 9.1 ESAs (Erythropoiesis Stimulating Agents)
- 9.2 G-CSFs (Granulocyte-colony Stimulating Factors)
- 9.3 Anti-emetics
- 9.4 Bisphosphonates
- 9.5 Opioids
- 9.6 NSAIDs & Others
- 10. Porters Five Forces
- 10.1 Overview
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Degree of Competition
- 10.5 Threat of New Entrants
- 10.6 Threat of Substitutes
- 11. Company Analysis
- 11.1 Bristol Myers Squibb
- 11.1.1 Overview
- 11.1.2 Recent Development
- 11.1.3 Revenue Analysis
- 11.2 Merc
- 11.2.1 Overview
- 11.2.2 Recent Development
- 11.2.3 Revenue Analysis
- 11.3 Eli Lilly
- 11.3.1 Overview
- 11.3.2 Recent Development
- 11.3.3 Revenue Analysis
- 11.4 Sino BioPharma
- 11.4.1 Overvie
- 11.4.2 Recent Development
- 11.4.3 Revenue Analysis
- 11.5 F Hoffmann-La Roche A
- 11.5.1 Overview
- 11.5.2 Recent Development
- 11.5.3 Revenue Analysis
- 11.6 Johnson & Johnson
- 11.6.1 Overview
- 11.6.2 Recent Development
- 11.6.3 Revenue Analysis
- 11.7 AbbVie Inc.
- 11.7.1 Overview
- 11.7.2 Recent Development
- 11.7.3 Revenue Analysis
- 11.8 AstraZeneca plc
- 11.8.1 Overview
- 11.8.2 Recent Development
- 11.8.3 Revenue Analysis
- List Of Figures:
- Figure-01: China Cancer Drugs Market (Billion US$), 2018 – 2021
- Figure-02: Forecast for – China Cancer Drugs Market (Billion US$), 2022 – 2027
- Figure-03: Therapy – Chemotherapy Market (Billion US$), 2018 – 2021
- Figure-04: Therapy – Forecast for Chemotherapy Market (Billion US$), 2022 – 2027
- Figure-05: Therapy – Targeted Therapy Market (Billion US$), 2018 – 2021
- Figure-06: Therapy – Forecast for Targeted Therapy Market (Billion US$), 2022 – 2027
- Figure-07: Therapy – Immunotherapy (Biologic Therapy) Market (Billion US$), 2018 – 2021
- Figure-08: Therapy – Forecast for Immunotherapy (Biologic Therapy) Market (Billion US$), 2022 – 2027
- Figure-09: Therapy – Hormonal Therapy Market (Billion US$), 2018 – 2021
- Figure-10: Therapy – Forecast for Hormonal Therapy Market (Billion US$), 2022 – 2027
- Figure-11: Indication – Blood Cancer Market (Billion US$), 2018 – 2021
- Figure-12: Indication – Forecast for Blood Cancer Market (Billion US$), 2022 – 2027
- Figure-13: Indication – Breast Cancer Market (Billion US$), 2018 – 2021
- Figure-14: Indication – Forecast for Breast Cancer Market (Billion US$), 2022 – 2027
- Figure-15: Indication – Gastrointestinal Cancer Market (Billion US$), 2018 – 2021
- Figure-16: Indication – Forecast for Gastrointestinal Cancer Market (Billion US$), 2022 – 2027
- Figure-17: Indication – Prostate Cancer Market (Billion US$), 2018 – 2021
- Figure-18: Indication – Forecast for Prostate Cancer Market (Billion US$), 2022 – 2027
- Figure-19: Indication – Lung Cancer Market (Billion US$), 2018 – 2021
- Figure-20: Indication – Forecast for Lung Cancer Market (Billion US$), 2022 – 2027
- Figure-21: Indication – Skin Cancer Market (Billion US$), 2018 – 2021
- Figure-22: Indication – Forecast for Skin Cancer Market (Billion US$), 2022 – 2027
- Figure-23: Indication – Ovarian Cancer Market (Billion US$), 2018 – 2021
- Figure-24: Indication – Forecast for Ovarian Cancer Market (Billion US$), 2022 – 2027
- Figure-25: Indication – Cervical Cancer Market (Million US$), 2018 – 2021
- Figure-26: Indication – Forecast for Cervical Cancer Market (Million US$), 2022 – 2027
- Figure-27: Indication – Kidney Cancer Market (Billion US$), 2018 – 2021
- Figure-28: Indication – Forecast for Kidney Cancer Market (Billion US$), 2022 – 2027
- Figure-29: Indication – Other Cancers Market (Billion US$), 2018 – 2021
- Figure-30: Indication – Forecast for Other Cancers Market (Billion US$), 2022 – 2027
- Figure-31: Drugs – ESAs (Erythropoiesis Stimulating Agents) Market (Billion US$), 2018 – 2021
- Figure-32: Drugs – Forecast for ESAs (Erythropoiesis Stimulating Agents) Market (Billion US$), 2022 – 2027
- Figure-33: Drugs – G-CSFs (Granulocyte-colony Stimulating Factors) Market (Billion US$), 2018 – 2021
- Figure-34: Drugs – Forecast for G-CSFs (Granulocyte-colony Stimulating Factors) Market (Billion US$), 2022 – 2027
- Figure-35: Drugs – Anti-emetics (Billion US$), 2018 – 2021
- Figure-36: Drugs – Forecast for Anti-emetics (Billion US$), 2022 – 2027
- Figure-37: Drugs – Bisphosphonates (Billion US$), 2018 – 2021
- Figure-38: Drugs – Forecast for Bisphosphonates (Billion US$), 2022 – 2027
- Figure-39: Drugs – Opioids (Billion US$), 2018 – 2021
- Figure-40: Drugs – Forecast for Opioids (Billion US$), 2022 – 2027
- Figure-41: Drugs – NSAIDs & Others (Billion US$), 2018 – 2021
- Figure-42: Drugs – Forecast for NSAIDs & Others (Billion US$), 2022 – 2027
- Figure-43: Bristol Myers Squibb – Global Revenue (Billion US$), 2018 – 2021
- Figure-44: Bristol Myers Squibb – Forecast for Global Revenue (Billion US$), 2022 – 2027
- Figure-45: Merck – Global Revenue (Billion US$), 2018 – 2021
- Figure-46: Merck – Forecast for Global Revenue (Billion US$), 2022 – 2027
- Figure-47: Eli Lilly – Global Revenue (Billion US$), 2018 – 2021
- Figure-48: Eli Lilly – Forecast for Global Revenue (Billion US$), 2022 – 2027
- Figure-49: Sino BioPharma – Global Revenue (Billion US$), 2018 – 2021
- Figure-50: Sino BioPharma – Forecast for Global Revenue (Billion US$), 2022 – 2027
- Figure-51: F Hoffmann-La Roche AG – Global Revenue (Billion US$), 2018 – 2021
- Figure-52: F Hoffmann-La Roche AG – Forecast for Global Revenue (Billion US$), 2022 – 2027
- Figure-53: Johnson & Johnson – Global Revenue (Billion US$), 2018 – 2021
- Figure-54: Johnson & Johnson – Forecast for Global Revenue (Billion US$), 2022 – 2027
- Figure-55: AbbVie Inc. – Global Revenue (Billion US$), 2018 – 2021
- Figure-56: AbbVie Inc. – Forecast for Global Revenue (Billion US$), 2022 – 2027
- Figure-57: AstraZeneca plc – Global Revenue (Billion US$), 2018 – 2021
- Figure-58: AstraZeneca plc – Forecast for Global Revenue (Billion US$), 2022 – 2027
- List Of Tables:
- Table-01: China Cancer Drugs Market Share by Therapy (Percent), 2018 – 2021
- Table-02: Forecast for – China Cancer Drugs Market Share by Therapy (Percent), 2022 – 2027
- Table-03: China Cancer Drugs Market Share by Indication (Percent), 2018 – 2021
- Table-04: Forecast for – China Cancer Drugs Market Share by Indication (Percent), 2022 – 2027
- Table-05: China Cancer Drugs Market Share by Drugs (Percent), 2018 – 2021
- Table-06: Forecast for – China Cancer Drugs Market Share by Drugs (Percent), 2022 – 2027
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
